Heat Shock Therapy to Improve Mitochondrial Function in Neuropathy

NCT05070741 | Terminated Results

• 1 other identifier: STUDY00143811
• Study Type: interventional
• Target: 3
• Locations: 1 country
• Sites: 1

Brief Summary

Sensory dysfunction as a result of peripheral nerve damage is a significant problem that leads to reduced quality of life for patients. The prevalence of sensory dysfunction in peripheral neuropathy associates with epidemic increases in prediabetes and diabetes, but also is relevant to chemotherapy treatments and genetic disorders. Clinical approaches to treat peripheral neuropathy and to stimulate axon growth in settings of peripheral axon loss are limited. Although new drugs will hopefully be forthcoming, the most promising approaches likely involve behavioral and lifestyle interventions. Mitochondrial dysfunction is emerging as a key cellular contribution to peripheral axon health and peripheral neuropathy. Mitochondrial deficiencies contribute to neuropathy and include impaired mitochondrial problems with trafficking, mitophagy, fission, and biogenesis. All of these are thought to lead to a bioenergetic crisis, ending in distal axonal degeneration, sensory dysfunction and pain. Heat shock proteins play a critically important role in cellular homeostasis and increasing heat shock protein functions within cells leads to a range of positive improvements, particularly in mitochondria. In addition, new evidence suggests that increasing heat shock protein responses in peripheral nerves has powerful, positive impacts on sensory function and neuropathy. Our interdisciplinary team will investigate the role of mitochondrial dysfunction in peripheral neuropathy and translate these approaches to improve treatment for patients with peripheral neuropathy. The investigators hypothesize that novel heat treatment interventions that improve mitochondrial function will improve metabolic symptoms and peripheral nerve mitochondria, leading to improvements in sensory function, via heat shock protein induction. The investigators will employ immersion heat treatment to elevate heat shock protein responses that induce positive changes in peripheral nerve mitochondria. One aspect is to confirm the efficacy, safety, and potential for heat treatment to improve sensory dysfunction in human patients with prediabetes. The goal of this proposal is 1) to test the breadth of heat treatment on various forms of neuropathy, 2) identify mechanisms in which heat treatment improves mitochondrial function, and 3) test the efficacy, safety, and potential for heat treatment to improve sensory dysfunction in human patients with prediabetes.

Conditions

PreDiabetes; Neuropathy

Outcome Measures

Primary Outcomes (3)

• Change in Fasting Blood Glucose (FBG)

  The study team will measure fasting blood glucose at baseline and post-intervention.

  At baseline and post-intervention (~4-5 weeks after first visit)

• Change in 2-hr Glucose

  The study team will measure 2-hr Glucose at baseline and post-intervention. To complete the oral glucose tolerance test (OGTT), the participant will drink a sweet, concentrated solution of glucose (Azer Scientific Glucola, 75 g) within 5 minutes. Afterwards, the participant will wait 2-hrs and blood will be drawn to test glucose and insulin levels.

  At baseline and post-intervention (~4-5 weeks after first visit)

• Change in Intraepidermal Nerve Fibers (IENF)

  The study team will count intraepidermal nerve fibers at baseline and post-intervention.

  At baseline and post-intervention (~4-5 weeks after first visit)

Secondary Outcomes (5)

• Change in Quantitative Sensory Testing (QST) Scores

  At baseline and post-intervention (~4-5 weeks after first visit)

• Change in Concentration of Heat Shock Protein 72

  At baseline and post-intervention (~4-5 weeks after first visit)

• Change in Concentration of Heat Shock Protein 25

  At baseline and post-intervention (~4-5 weeks after first visit)

• Change in Concentration of Heat Shock Protein Transcription Factor 1

  At baseline and post-intervention (~4-5 weeks after first visit)

• Utah Early Neuropathy Scale (UENS)

  At baseline and post-intervention (~4-5 weeks after first visit)

Study Arms (1)

Heat Therapy Treatment

EXPERIMENTAL

This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm). Subjects will complete 12 heat therapy treatments over the course of 4 weeks. Within 24-48 hours after the last heat therapy experience, post-treatment laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm) will be performed.

Behavioral: Heat Therapy

Interventions

Heat Therapy BEHAVIORAL

Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (\~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged \~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted \~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.

Heat Therapy Treatment

Eligibility Criteria

• Age: 45 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• both males and females,
• ages 45-75,
• have suspected or diagnosed prediabetes with or without neuropathy (to be confirmed at pre-intervention evaluation).

You may not qualify if:

• skin conditions, circulatory insufficiency, or open wounds in the leg that would interfere with healing from a biopsy;
• stroke or other significant nervous system pathology;
• lidocaine allergy;
• anticipated difficulty with blood clotting due to disorder or use of a blood thinner such as Coumadin, Xarelto, or Eliquis;
• use of any medication used to treat abnormal blood glucose such as Metformin;
• body weight \> 350 lbs.;
• history of anemia or vitamin b12 deficiency;
• clinical anemia (hematocrit \<32 for women, \<36 for men);
• abnormal SPEP result;
• history of cancer or chemotherapy treatment;
• current or recent use (within the last 6 months) of artificial fingernails / nail enhancements that would interfere with quantitative sensory testing;
• no special classes of subjects such as fetuses, neonates, pregnant women, prisoners, institutionalized individuals, non-English speaking individuals, or other who may be considered vulnerable populations will be included in this study.
• Withdrawal/Termination criteria: Prediabetes will be determined using the American Diabetes Association (ADA) Diabetes Management Guidelines. The subject will meet the criteria for a diagnosis of pre-diabetes if the subject has one or more positive test(s) for either A1c (5.7-6.4%), fasting glucose (100-125 mg/dl), or 2-hr oral glucose tolerance test (140-199 mg/dl). If at pre-intervention evaluation, the subject does not meet the criteria for prediabetes (lower than the above-mentioned range), meets the ADA criteria for diabetes (higher than the above-mentioned range), the subject will be considered a screen fail and will not progress to skin biopsy or intervention.

Sponsors & Collaborators

• University of Kansas Medical Center: lead

Study Sites (1)

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

MeSH Terms

Conditions

Prediabetic State

Interventions

Diathermy

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Hyperthermia, Induced; Therapeutics

Limitations and Caveats

We were able to enroll 3 subjects, though 1 was a screen fail and unable to start intervention. Unfortunately recruitment was difficult due to 1) troubles identifying the population target (pre-diabetic with idiopathic neuropathy), 2) strict timing requirements of the study and 3) potential subject concerns regarding the COVID pandemic.

Results Point of Contact

• Title: Paige Geiger, PhD
• Organization: University of Kansas Medical Center

pgeiger@kumc.edu

913-588-7408

Study Officials

• Paige Geiger, PhD

  University of Kansas Medical Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Molecular & Integrative Physiology

Model Details: This prospective, observational cohort pilot study will recruit 20 patients with prediabetes with or without peripheral neuropathy (painful and non-painful) to participate in a 4-week heat therapy intervention. After screening, informed consent, and enrollment into the study, subjects will undergo a pre-intervention evaluation that will assess metabolic biomarkers and heat shock protein levels (blood), peripheral neuropathy, and epidermal evaluation (skin biopsy). After the skin biopsy has the appropriate time to heal (approximately 7-14 days), the subjects will undergo 45-minute heat treatments in 40°C water, three times weekly, for 4 weeks. After completion of heat treatments, subjects will undergo a repeated post-intervention evaluation and skin biopsy. Statistical approaches will compare pre- and post-heat therapy measures.

Study Record Dates

• First Submitted: September 27, 2021
• First Posted: October 7, 2021
• Study Start: July 27, 2020
• Primary Completion: July 11, 2022
• Study Completion: July 11, 2022
• Last Updated: January 24, 2025
• Results First Posted: January 24, 2025

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)